Difference between revisions of "Procarbazine (Matulane)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Anaplastic glioma]] |
*[[CNS lymphoma]] | *[[CNS lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| + | *[[Glioblastoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| + | *[[Low-grade glioma]] | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 34: | Line 39: | ||
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
| − | [[Category: | + | [[Category:Anaplastic glioma medications]] |
[[Category:Central nervous system (CNS) lymphoma medications]] | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Glioblastoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Low-grade glioma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1969]] | [[Category:Drugs FDA approved in 1969]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 15:55, 20 January 2018
General information
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anaplastic glioma
- CNS lymphoma
- Follicular lymphoma
- Glioblastoma
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
Diseases for which it was used
Patient drug information
- Procarbazine (Matulane) patient drug information (Chemocare)[3]
- Procarbazine (Matulane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/22/1969: Initial FDA approval
Also known as
- Code names: NCI-C01810, Ro 4-6467/1
- Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, P-Carbazine, procarbazine hydrochloride
- Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carzine
References
Categories:
- Drug index
- Oral medications
- Alkylating agents
- DNA synthesis inhibitors
- Anaplastic glioma medications
- Central nervous system (CNS) lymphoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Drugs FDA approved in 1969
- WHO Essential Cancer Medicine